4 articles
Science Corporation closes a $230 million Series C led by Khosla Ventures and Lightspeed, pushing its valuation past $1 billion as it targets European launch of the PRIMA vision-restoration implant by mid-2026.
The neurotechnology company founded by Neuralink co-founder Max Hodak has raised $230 million at a $1.25 billion valuation, bringing its total funding to $489 million as it pushes toward commercialization of its retinal implant.
Max Hodak's neurotechnology company secures major Series C funding as the BCI industry consolidates around clinical applications and commercial viability.
A new partnership between Science Corp and Neurosoft AI aims to dramatically reduce the cost and timeline of brain-computer interface clinical trials through shared infrastructure and software tools.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. Unsubscribe anytime. We respect your privacy.